A case of multiple myeloma with nuclear hypersegmentation after MP/VAD/VCAP-IFN therapies with a good prognosis.
Nara
M
M
Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Suzuki
K
K
Inoue
Y
Y
Enomoto
H
H
Saito
T
T
Fujioka
S
S
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D002467:Cell Nucleus / Q000473:pathology*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008854:Microscopy, Electron; D009101:Multiple Myeloma / Q000473:pathology* / Q000628:therapy; D010950:Plasma Cells / Q000648:ultrastructure*; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage
D016898:Interferon-alpha; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D011241:Prednisone